Park et al.9 harness lentivirally transduced CD19-CAR-T cells with CD3ζ and CD28 to treat R/R B-ALL, and report that 83% of patients achieve CR and 67% of patients achieve CR and remain MRD negative. This evidence concerns the gene CD247 and acute lymphoblastic leukemia.